166 related articles for article (PubMed ID: 37224415)
1. Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients.
Boston B; Ipe D; Capitanescu B; Gresita A; Hamlet S; Love R; Hadjiargyrou M; Huang CL; Nusem I; Miroiu RI; Popa-Wagner A; Warnke PH; Petcu EB
J Am Geriatr Soc; 2023 Aug; 71(8):2640-2652. PubMed ID: 37224415
[TBL] [Abstract][Full Text] [Related]
2. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
3. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
4. Emerging antiresorptive medications and their potential implications for dental surgeries.
Aminoshariae A; Donaldson M; Horan M; Mackey SA; Kulild JC; Baur D
J Am Dent Assoc; 2022 Jul; 153(7):649-658. PubMed ID: 35277242
[TBL] [Abstract][Full Text] [Related]
5. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
6. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.
Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC
Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.
Zhao N; Li QX; Wang YF; Qiao Q; Huang HY; Guo CB; Guo YX
BMC Oral Health; 2023 May; 23(1):330. PubMed ID: 37245004
[TBL] [Abstract][Full Text] [Related]
8. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
9. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
[TBL] [Abstract][Full Text] [Related]
10. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
11. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.
Jung S; Kim J; Park JH; Kim KY; Kim HJ; Park W
Sci Rep; 2022 May; 12(1):8641. PubMed ID: 35606457
[TBL] [Abstract][Full Text] [Related]
12. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
13. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw.
Schwaneck EC; Streit A; Krone M; Hartmann S; Müller-Richter U; Kübler AC; Gadeholt O; Schmalzing M; Tony HP; Brands RC
Z Rheumatol; 2020 Mar; 79(2):203-209. PubMed ID: 30796524
[TBL] [Abstract][Full Text] [Related]
15. Medication-related osteonecrosis of the jaw: A literature review and update.
Kuroshima S; Al-Omari FA; Sasaki M; Sawase T
Genesis; 2022 Sep; 60(8-9):e23500. PubMed ID: 36106755
[TBL] [Abstract][Full Text] [Related]
16. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
Nisi M; Karapetsa D; Gennai S; Ramaglia L; Graziani F; Gabriele M
J Craniomaxillofac Surg; 2018 Jul; 46(7):1153-1158. PubMed ID: 29802059
[TBL] [Abstract][Full Text] [Related]
17. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).
Aguirre JI; Castillo EJ; Kimmel DB
Bone; 2021 Dec; 153():116184. PubMed ID: 34520898
[TBL] [Abstract][Full Text] [Related]
18. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
19. The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.
Yüce MO; Adalı E; Işık G
Clin Oral Investig; 2021 Jul; 25(7):4529-4541. PubMed ID: 33392802
[TBL] [Abstract][Full Text] [Related]
20. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]